참고문헌
- Adelstein DJ, Li Y, Adams GL, Wagner H, Kish JA, Ensley JF, et al. An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients With Unresectable Squamous Cell Head and Neck Cancer. J Clin Oncol. 2003;21:92-98. https://doi.org/10.1200/JCO.2003.01.008
- Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al. Final Results of the 94-01 French Head and Neck Oncology and Radiotherapy Group Randomized Trial Comparing Radiotherapy Alone With Concomitant Radiochemotherapy in Advanced-Stage Oropharynx Carcinoma. J Clin Oncol. 2004;22:69-76. https://doi.org/10.1200/JCO.2004.08.021
- Olmi P, Crispino S, Fallai C, Torri V, Rossi F, Bolner A, et al. Locoregionally advanced carcinoma of the oropharynx: Conventional radiotherapy vs. accelerated hyperfractionated radiotherapy vs. concomitant radiotherapy and chemotherapy-a multicenter randomized trial. Int J Radiat Oncol Biol Phys. 2003;55: 78-92. https://doi.org/10.1016/S0360-3016(02)03792-6
- Jin IG, Kim JH, Wu HG, Hwang SJ. Effect of mesenchymal stem cells and platelet-derived growth factor on the healing of radiation induced ulcer in rats. Tissue Eng Regen Med. 2016;13:78-90. https://doi.org/10.1007/s13770-015-0055-x
- Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, et al. Randomized Phase III Trial to Test Accelerated Versus Standard Fractionation in Combination With Concurrent Cisplatin for Head and Neck Carcinomas in the Radiation Therapy Oncology Group 0129 Trial: Long-Term Report of Efficacy and Toxicity. J Clin Oncol. 2014;32:3858-3867. https://doi.org/10.1200/JCO.2014.55.3925
- Zandberg DP, Cullen K, Bentzen SM, Goloubeva OG. Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: Analysis of the SEER-medicare linked database. Oral Oncol. 2018;86:132-140. https://doi.org/10.1016/j.oraloncology.2018.09.023
- Parsons JT, Mendenhall WM, Stringer SP, Amdur RJ, Hinerman RW, Villaret DB, et al. Squamous cell carcinoma of the oropharynx. Cancer. 2002;94:2967-2980. https://doi.org/10.1002/cncr.10567
- Bernier J, Cooper JS. Chemoradiation after surgery for high-risk head and neck cancer patients: How strong is the evidence? Oncologist. 2005;10:215-224. https://doi.org/10.1634/theoncologist.10-3-215
- Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer. N Engl J Med. 2010;363:24-35. https://doi.org/10.1056/NEJMoa0912217
- Petrelli F, Luciani A, Ghidini A, Cherri S, Gamba P, Maddalo M, et al. Treatment de-escalation for HPV+ oropharyngeal cancer: A systematic review and meta-analysis. Head Neck. 2022;44:1255-1266. https://doi.org/10.1002/hed.27019
- Adelstein DJ, Ismaila N, Ku JA, Burtness B, Swiecicki PL, Mell L, et al. Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol. 2019;37:1578-1589. https://doi.org/10.1200/JCO.19.00441
- National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Head and Neck Cancers, Version 2.2022.
- Cramer JD, Ferris RL, Kim S, Duvvuri U. Primary surgery for human papillomavirus-associated oropharyngeal cancer: Survival outcomes with or without adjuvant treatment. Oral Oncol. 2018;87:170-176. https://doi.org/10.1016/j.oraloncology.2018.10.039
- Kang JJ, Yu Y, Chen L, Zakeri K, Gelblum DY, McBride SM, et al. Consensuses, controversies, and future directions in treatment deintensification for human papillomavirus-associated oropharyngeal cancer. CA Cancer J Clin [Preprint]. 2022 [cited 2022 Oct 28];1-34. Available from: 10.3322/caac.21758
- Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): A comprehensive analysis by tumour site. Radiother Oncol. 2011;100:33-40. https://doi.org/10.1016/j.radonc.2011.05.036
- Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578. https://doi.org/10.1056/NEJMoa053422
- Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): A randomised, multicentre, non-inferiority trial. Lancet. 2019;393:40-50. https://doi.org/10.1016/S0140-6736(18)32779-X
- Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): An open-label randomised controlled phase 3 trial. Lancet. 2019;393:51-60. https://doi.org/10.1016/S0140-6736(18)32752-1
- Gebre-Medhin M, Brun E, Engstrom P, Haugen Cange H, Hammarstedt-Nordenvall L, Reizenstein J, et al. ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer. J Clin Oncol. 2021;39:38-47. https://doi.org/10.1200/jco.20.02072
- Rischin D, King M, Kenny L, Porceddu S, Wratten C, Macann A, et al. Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) - A Trans-Tasman Radiation Oncology Group Study. Int J Radiat Oncol Biol Phys. 2021;111:876-886. https://doi.org/10.1016/j.ijrobp.2021.04.015
- Yom SS, Torres-Saavedra P, Caudell JJ, Waldron JN, Gillison ML, Xia P, et al. Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002). J Clin Oncol. 2021;39:956-965. https://doi.org/10.1200/JCO.20.03128
- Wang MB, Liu IY, Gornbein JA, Nguyen CT. HPV-Positive Oropharyngeal Carcinoma: A Systematic Review of Treatment and Prognosis. Otolaryngol Head Neck Surg. 2015;153:758-769. https://doi.org/10.1177/0194599815592157
- Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, et al. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): An open-label, phase 2, randomised trial. The Lancet Oncology. 2019;20:1349-1359. https://doi.org/10.1016/s1470-2045(19)30410-3
- Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, et al. Randomized Trial of Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Long-Term Results of the ORATOR Trial. J Clin Oncol. 2022;40:866-875. https://doi.org/10.1200/JCO.21.01961
- Nichols AC, Lang P, Prisman E, Berthelet E, Tran E, Hamilton S, et al. Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2): Study protocol for a randomized phase II trial. BMC Cancer. 2020;20:125.
- Palma DA, Prisman E, Berthelet E, Tran E, Hamilton S, Wu J, et al. Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: The ORATOR2 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2022;8:845-851. https://doi.org/10.1001/jamaoncol.2022.0615
- Quan DL, Sukari A, Nagasaka M, Kim H, Cramer JD. Gastrostomy tube dependence and patient-reported quality of life outcomes based on type of treatment for human papillomavirus-associated oropharyngeal cancer: Systematic review and meta-analysis. Head Neck. 2021;43:3681-3696. https://doi.org/10.1002/hed.26829
- Chera BS, Amdur RJ, Tepper JE, Tan X, Weiss J, Grilley-Olson JE, et al. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma. Cancer. 2018;124:2347-2354. https://doi.org/10.1002/cncr.31338
- Chera BS, Amdur RJ, Green R, Shen C, Gupta G, Tan X, et al. Phase II Trial of De-Intensified Chemoradiotherapy for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma. J Clin Oncol. 2019;37:2661-2669. https://doi.org/10.1200/jco.19.01007
- Dagan R, Holtzman AL, Bryant CM, Mendenhall WM, Hitchcock KE, Park J, et al. De-Intensified (DI) IMPT vs. IMRT(Chemo) for HPV-Associated Oropharynx Cancer (HPV-OPC): Initial Quality of Life (QOL) Results From a Prospective, Multi-Institutional Trial. Int J Radiat Oncol Biol Phys. 2021;111 Suppl 3: e406-407.
- Chen AM, Felix C, Wang PC, Hsu S, Basehart V, Garst J, et al. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: A single-arm, phase 2 study. Lancet Oncol. 2017;18:803-811. https://doi.org/10.1016/S1470-2045(17)30246-2
- Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, et al. E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx- ECOG-ACRIN cancer research group. J Clin Oncol. 2017;35:490-497.
- Misiukiewicz K, Gupta V, Miles BA, Bakst R, Genden E, Selkridge I, et al. Standard of care vs reduced-dose chemo-radiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trial. Oral Oncol. 2019;95:170-177. https://doi.org/10.1016/j.oraloncology.2019.06.021
- Posner MR, Misiukiewicz K, Miles BA, Sharma S, Gupta V, Genden EM, et al. Survival (OS) and progression-free survival (PFS) results after induction chemotherapy (IC) followed by de-escalated chemoradiotherapy (RDCRT) for locally advanced (LA) HPV positive oropharynx cancer (HPVOPC). J Clin Oncol. 2021;39 Suppl 15:6058.
- Rosenberg AJ, Agrawal N, Pearson A, Gooi Z, Blair E, Cursio J, et al. Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience. Oral Oncol. 2021;122:105566.
- Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N, Melotek JM, et al. OPTIMA: A phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer. Ann Oncol. 2019;30:297-302. https://doi.org/10.1093/annonc/mdy522
- Kim R, Hahn S, Shin J, Ock CY, Kim M, Keam B, et al. The Effect of Induction Chemotherapy Using Docetaxel, Cisplatin, and Fluorouracil on Survival in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Meta-Analysis. Cancer Res Treat. 2016;48:907-916.
- Lee NY, Sherman EJ, Schoder H, McBride SM, Yu Y, Kang J, et al. The 30 ROC trial: Precision intra-treatment imaging guiding major radiation reduction in human papillomavirus related oropharyngeal cancer. J Clin Oncol. 2021;39 Suppl 15:6019.
- Riaz N, Sherman E, Pei X, Schoder H, Grkovski M, Paudyal R, et al. Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. J Natl Cancer Inst. 2021;113:742-751. https://doi.org/10.1093/jnci/djaa184
- Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, et al. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005;27:843-850. https://doi.org/10.1002/hed.20279
- Ferris RL, Flamand Y, Weinstein GS, Li S, Quon H, Mehra R, et al. Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16++ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311). J Clin Oncol. 2022;40:138-149.
- Ma DJ, Price KA, Moore EJ, Patel SH, Hinni ML, Garcia JJ, et al. Phase II Evaluation of Aggressive Dose De-Escalation for Adjuvant Chemoradiotherapy in Human Papillomavirus-Associated Oropharynx Squamous Cell Carcinoma. J Clin Oncol. 2019;37:1909-1918. https://doi.org/10.1200/jco.19.00463
- Ma DJ, Price K, Eric MJ, Patel SH, Hinni ML, Ginos BF, et al. Long-Term Results for MC1273, A Phase II Evaluation of De-Escalated Adjuvant Radiation Therapy for Human Papillomavirus Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ (HPV+ OPSCC). Int J Radiat Oncol Biol Phys. 2021;111 Suppl 3:S61.
- Ma DJ, Price K, Moore EJ, Patel SH, Hinni ML, Fruth B, et al. Non-Inferiority Margin and Nodal Analysis of De-Escalated Adjuvant Radiation Therapy (DART) for HPV-Related Oropharyngeal Squamous Cell Carcinoma (OPSCC): A Preplanned Pooled Analysis of MC1273 & MC1675. Int J Radiat Oncol Biol Phys. 2022;112:e3-4.
- Ma DM, Price K, Moore EJ, Patel SH, Hinni ML, Fruth B, et al. MC1675, a Phase III Evaluation of De-Escalated Adjuvant Radiation Therapy (DART) vs. Standard Adjuvant Treatment for Human Papillomavirus Associated Oropharyngeal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys. 2021;111:1324.